Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
AstraZeneca
Actuate Therapeutics Inc.
Verastem, Inc.
Incyte Corporation
AstraZeneca
Dana-Farber Cancer Institute
Eli Lilly and Company
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Eli Lilly and Company
Novartis
Wake Forest University Health Sciences
AstraZeneca
University Health Network, Toronto
The Netherlands Cancer Institute
Eikon Therapeutics
Incyte Corporation
AstraZeneca
Centre Francois Baclesse
BeiGene
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
Deciphera Pharmaceuticals, LLC
Jules Bordet Institute
Genentech, Inc.
Taiho Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
G1 Therapeutics, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OHSU Knight Cancer Institute
Icahn School of Medicine at Mount Sinai
SCRI Development Innovations, LLC
National Cancer Institute (NCI)
Canadian Cancer Trials Group
Shanghai Henlius Biotech
OncoSec Medical Incorporated
Nektar Therapeutics
University of California, San Francisco
H. Lee Moffitt Cancer Center and Research Institute
The Netherlands Cancer Institute
Fudan University